Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Nivvis is a biotechnology company specializing in high-throughput single-cell proteomics to advance precision medicine and drug discovery. Founded by Dr. Nikolai Slavov, the company commercializes innovative mass spectrometry-based technologies, such as SCoPE2 and plexDIA, which were developed at Northeastern University. These platforms allow for the quantification of thousands of proteins across thousands of individual cells, providing a much higher resolution of biological processes than traditional bulk methods. By capturing the functional state of cells, Nivvis enables researchers to identify novel biomarkers, map cellular hierarchies, and understand drug mechanisms of action at a granular level. The company's services and technology are particularly applicable in oncology, immunology, and developmental biology, where cellular heterogeneity is a critical factor. Nivvis aims to bridge the gap between genomic data and clinical outcomes by providing deep, scalable proteomic insights.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Nivvislabs.